In brief: Antipsychotic choice in early-onset schizophrenia

In brief

Antipsychotic choice in early-onset schizophrenia

Published: December, 2008

Another study raises questions about the relative efficacy of first- and second-generation antipsychotics.

In the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) study, investigators randomly assigned 119 patients, ages 8 to 19, diagnosed with early-onset schizophrenia or schizoaffective disorder to treatment with the first-generation drug molindone (Moban) or one of two second-generation drugs, olanzapine (Zyprexa) or risperidone (Risperdal). Some patients were just diagnosed or "first episode," while others had chronic illness. Medications were prescribed at moderate doses.

To continue reading this article, you must log in.
  • Research health conditions
  • Check your symptoms
  • Prepare for a doctor's visit or test
  • Find the best treatments and procedures for you
  • Explore options for better nutrition and exercise

New subscriptions to Harvard Health Online are temporarily unavailable. Click the button below to learn about our other subscription offers.

Learn More »